Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 3/2020

01-06-2020 | Hepatocellular Carcinoma | Original Article

Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma

Authors: Reham M. Abd El-Baky, Helal F. Hetta, Gopala Koneru, Marwa Ammar, Engy A. Shafik, Dina A Mohareb, Muhammad Abbas El-Masry, Haidi K. Ramadan, Mohamed Zakaria Abu Rahma, Michael A. Fawzy, Moustafa Fathy

Published in: Immunologic Research | Issue 3/2020

Login to get access

Abstract

Hepatitis C virus (HCV) is considered leading cause of cirrhosis and hepatocellular carcinoma (HCC). We aimed to examine the association of IL-6 and IL-10 single-nucleotide polymorphisms with the progression of chronic HCV (CHC) infection to cirrhosis and HCC. For comparative purposes, four groups were enrolled; chronic HCV group (CHC, n = 22), HCV-related liver cirrhosis group (HCV-LC, n = 22), HCV-related HCC group (HCV-HCC, n = 54), and an apparently healthy control group (controls, n = 48). HCC diagnosis and staging were in concordance to Barcelona Clinic Liver Cancer (BCLC) staging system. IL-6 rs-1474347 and IL-10 rs-1800896 genotyping was performed by allelic (VIC- and FAM-labeled) discrimination method using assay-on-demand TaqMan real-time PCR assays. For IL-6 rs1474347, the AA genotype was more frequent in CHC, HCV-LC, and HCV-HCC compared to controls. Also, the IL-6 rs1474347 AC genotype was favorable for the progression of HCV chronic infection to cirrhosis and HCC. On the other hand, the IL-10 rs1800896 TT genotype was found to be prominent in the HCC group. Additionally, the IL-10 rs180096 TT genotype was favorable for the progression of chronic HCV infection to cirrhosis and HCC. Furthermore, higher levels of AFP were observed in HCC patients with IL-6 rs1474347 AA genotype and HCC patients with IL-10 rs1800896 CC and TT genotypes. Screening for IL-6 rs 1474347 AC genotype and IL-10 rs180096 TT genotype as well as the determination of AFP level showed to be good markers for examining the susceptibility of HCV Egyptian patients to develop cirrhosis and HCC.
Literature
1.
Raphael S, Yangde Z, YuXiang C (2012) Hepatocellular carcinoma: focus on different aspects of management ISRN Oncology. 2012. Article ID 421673:12.
2.
Obienu O, Nwokediuko S, Malu A, Lesi OA. Risk factors for hepatitis C virus transmission obscure in nigerian patients. Gastroenterol Res Pract. 2011;2011.
3.
Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, et al. Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology. J Gastroenterol Hepatol. 2015;30(10):1543–51.PubMedPubMedCentral
4.
Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, et al. Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis. J Med Microbiol. 2016;65(8):703–12.PubMedPubMedCentral
5.
Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, et al. Association between IL28b rs12979860 single nucleotide polymorphism and the frequency of colonic T reg in chronically HCV-infected patients. Arch Virol. 2016;161(11):3161–9.PubMedPubMedCentral
6.
Hetta HF, Mehta MJ, Shata MTM. Gut immune response in the presence of hepatitis C virus infection. World J Immunol. 2014;4(2):52–62.
7.
Zahran AM, Ashmawy AM, Rayan A, Elkady A, Elsherbiny NM, Hetta HF. Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma. Egypt J Immunol. 2018;25:45–52.PubMed
8.
Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91.PubMed
9.
Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006;43(5):915–22.PubMed
10.
El-Sabah A, El-Metwally M, Abozinadah N. Hepatitis C and B virus in schistosomiasis patients on oral or parenteral treatment. J Egypt Soc Parasitol. 2011;41(2):307–14.PubMed
11.
Hetta HF, Zahran AM, Mansor SG, Abdel-Malek MO, Mekky MA, Abbas WA. Frequency and implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. J Med Virol. 2019;91(7):1319–28.PubMed
12.
Zahran AM, Nafady-Hego H, Mansor SG, Abbas WA, Abdel-Malek MO, Mekky MA, et al. Increased frequency and FOXP3 expression of human CD8+ CD25High+ T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma. Hum Immunol. 2019;80(7):510–6.PubMed
13.
El-Sadawy M, Ragab H, El-Toukhy H, el-Mor A-L, Mangoud A, Eissa M, et al. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. J Egypt Soc Parasitol. 2004;34(1 Suppl):367–84.PubMed
14.
Kalil K, Farghally H, Hassanein K, Abdel Sayed A, Hassanein F (2010) Hepatitis C virus infection among paediatric patients attending University of Assiut Hospital, Egypt.
15.
16.
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.PubMed
17.
Abd Ellah NH, Tawfeek HM, John J, Hetta HF. Nanomedicine as a future therapeutic approach for hepatitis C virus. Nanomedicine. 2019;14(11):1471–91.PubMed
18.
Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clinical Liver Disease. 2012;1(6):180–2.PubMed
19.
Mekky MA, Abdel-Malek MO, Osman HA, Abdel-Aziz EM, Hashim A-KA, Hetta HF, et al. Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease. Clini Res Hepatol Gas. 2019;43(1):82–7.
20.
Chaturvedi VK, Singh A, Dubey SK, Hetta HF, John J, Singh M. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microb Pathog. 2019;128:184–94.PubMed
21.
Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study. Infect Drug Resist. 2019;12:273.PubMedPubMedCentral
22.
Hetta HF, Elkady A, Morsy KH, Mohamed IS, Ibrahim MA. Serum level of IL17a among cirrhotic hepatitis C virus infected patients with incidence of diabetes mellitus. Egypt J Immunol. 2017;24(1):79–88.PubMed
23.
Hetta HF. Circulating IL17A and IFN-gamma serum levels in cirrhotic hepatitis C virus infected patients with autoimmune thyroiditis. Int J Curr Microbiol App Sci. 2017;6(3):1972–83.
24.
Hetta HF, Elkady A, Meshaal AK. TH17/TH1 role in endocrine disorders among chronic HCV infected patients. Int J Curr Microbiol App Sci. 2017;6(8):2542–51.
25.
Shata MTM, Abdel-Hameed EA, Hetta HF, Sherman KE. Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2). J Clin Pathol. 2013;66(11):967–75.PubMedPubMedCentral
26.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMed
27.
Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, et al. Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine. 2017;89:62–7.PubMed
28.
Liu H, Lyu D, Zhang Y, Sheng L, Tang N. Association between the IL-6 rs1800795 polymorphism and the risk of cervical cancer: a meta-analysis of 1210 cases and 1525 controls. Technology in cancer research & treatment. 2017;16(5):662–7.
29.
Ad’hiah AH, Mahmood AS, Al-kazaz A-KA, Mayouf KK. Gene expression and six single nucleotide polymorphisms of interleukin-6 in rheumatoid arthritis: a case-control study in Iraqi patients. Alexandria J Med. 2018;54(4):639–45.
30.
Hassan EA, Ahmed EH, Nafee AM, El-Gafary N, Hetta HF, El-Mokhtar MA. Regulatory T cells, IL10 and IL6 in HCV related hepatocellular carcinoma after transarterial chemoembolization (TACE). Egypt J Immunol. 2019;26:69–78.PubMed
31.
Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19(1):683–765.PubMed
32.
Hetta H, Elkady A, Tohamy T, Badary M. Regulatory B cells: key players in hepatocellular carcinoma progression. Gastroenterol Hepatol Open Access. 2016;5(2):00136.
33.
34.
Aroucha DC, Carmo RF, Vasconcelos LRS, Lima RE, Mendonça TF, Arnez LE, et al. TNF-α and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals. J Med Virol. 2016;88(9):1587–95.PubMed
35.
36.
Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, et al. Evaluating the role of cellular immune responses in the emergence of HCV NS3 resistance mutations during protease inhibitor therapy. Viral Immunol. 2016;29(4):252–8.PubMedPubMedCentral
37.
Feldmann G, Nischalke HD, Nattermann J, Banas B, Berg T, Teschendorf C, et al. Induction of Interleukin-6 by hepatitis C virus core protein in hepatitis C–associated mixed cryoglobulinemia and B-cell non–Hodgkin's lymphoma. Clin Cancer Res. 2006;12(15):4491–8.PubMed
38.
Zahran AM, Zahran ZAM, El-Badawy O, Abdel-Rahim MH, Ali WA, Rayan A, et al. Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. Immunol Res. 2019;67(2–3):157–65.PubMed
39.
Smith AJ, D’Aiuto F, Palmen J, Cooper JA, Samuel J, Thompson S, et al. Association of serum interleukin-6 concentration with a functional IL6− 6331T> C polymorphism. Clin Chem. 2008;54(5):841–50.PubMed
40.
Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4–5):357–68.PubMed
41.
Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasa M, Cervello M, et al. IL-6−174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. Omics. 2011;15(3):183–6.PubMed
42.
Reichner JS, Mulligan JA, Palla ME, Hixson DC, Albina JE, Bland KI. Interleukin-6 production by rat hepatocellular carcinoma cells is associated with metastatic potential but not with tumorigenicity. Arch Surg. 1996;131(4):360–5.PubMed
43.
44.
Malaguarnera M, Di IF, Laurino A, Romeo M, Giugno I, Trovato B. Role of interleukin 6 in hepatocellular carcinoma. Bull Cancer. 1996;83(5):379–84.PubMed
45.
46.
47.
Shaikh FH, Zeb S, Chandio SA, Munaf A, Ghori MA, Memon MS, et al. Frequency of deaths in hepatitis C virus infected hepatocellular carcinoma patients and its relationship with raised serum alpha-fetoprotein levels. J Pak Med Assoc. 2016;66(1):34–6.PubMed
48.
Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci. 2005;37(2):111–3.PubMed
49.
50.
Gao Q, Zhang S, Wu L, Jia M, Mi Y, Liu D. Association of IL-10-1082 and IL-10-592 polymorphisms with chronic hepatitis B and/or hepatitis C virus infection among plasma donors in a rural area of Hebei Province, China. Wei sheng yan jiu = Journal of hygiene research. 2011;40(6):709–13.PubMed
51.
52.
Yao L, Xing S, Fu X, Song H, Wang Z, Tang J, et al. Association between interleukin-10 gene promoter polymorphisms and susceptibility to liver cirrhosis. Int J Clin Exp Pathol. 2015;8(9):11680–4.PubMedPubMedCentral
53.
54.
Haque SS, Kumari R, Muzaffar A, Kumar U, Sharan A, Kumari B. Estimation of serum alpha feto-protein (AFP), interlukin-6 and Des-?-carboxyprothrombin (DCP) in case of hepatocellular carcinoma. Bangladesh Journal of Medical Science. 2016;15(2):230–3.
Metadata
Title
Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma
Authors
Reham M. Abd El-Baky
Helal F. Hetta
Gopala Koneru
Marwa Ammar
Engy A. Shafik
Dina A Mohareb
Muhammad Abbas El-Masry
Haidi K. Ramadan
Mohamed Zakaria Abu Rahma
Michael A. Fawzy
Moustafa Fathy
Publication date
01-06-2020
Publisher
Springer US
Published in
Immunologic Research / Issue 3/2020
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-020-09126-8

Other articles of this Issue 3/2020

Immunologic Research 3/2020 Go to the issue

Original Article

The ratio of CD163-positive macrophages to Iba1-positive macrophages is low in the intima in the early stage of cutaneous arteritis

Original Article

Big data highlights the association between psoriasis and fibromyalgia: a population-based study

Review

COVID 19: a clue from innate immunity

Original Article

Jeffrey’s insights: Jeffrey Modell Foundation’s global genetic sequencing pilot program to identify specific primary immunodeficiency defects to optimize disease management and treatment

Original Article

Soluble CD83 suppresses experimental food allergy via regulating aberrant T helper 2 responses

Brief report

Increased expression of proinflammatory cytokines and iNOS in the neocortical microvasculature of patients with temporal lobe epilepsy